2018
DOI: 10.2174/1871520616666160817104529
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical Toxicity of Paclitaxel Biopolymer Formulation

Abstract: Thus, the PBF as a prolong drug needs to correct its parameters for further drug formulation development.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…However, paclitaxel has obvious toxicity. For example, it can cause bone marrow suppression and peripheral neuropathy ( 22 ). However, in a first-line study of non-small cell lung (NSCLC), nab-paclitaxel combined with carboplatin was used, and the results showed that the combination could reduce cytotoxicity ( 23 ).…”
Section: Paclitaxel Binding Domainmentioning
confidence: 99%
“…However, paclitaxel has obvious toxicity. For example, it can cause bone marrow suppression and peripheral neuropathy ( 22 ). However, in a first-line study of non-small cell lung (NSCLC), nab-paclitaxel combined with carboplatin was used, and the results showed that the combination could reduce cytotoxicity ( 23 ).…”
Section: Paclitaxel Binding Domainmentioning
confidence: 99%